{"slug":"ss-31-skin","verification":{"valid":true,"entries":2,"head":"5300ffdf89b0387cca17d13259fe81c2881e2f35fe775149692419184d45e683"},"energy":{"passes":2,"tokens_in":26702,"tokens_out":2538,"tokens_total":29240,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5300ffdf89b0387cca17d13259fe81c2881e2f35fe775149692419184d45e683"},"provenance":[{"ts":"2026-06-29T23:45:53.599Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Skin\nSlug: ss-31-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into o","response":"{\n  \"slug\": \"ss-31-skin\",\n  \"title\": \"SS-31 (Elamipretide) for Skin: Mitochondrial Evidence Graded\",\n  \"body\": \"## What's breaking down\\n\\nSkin aging involves layers of cellular decline. One key layer is mitochondrial dysfunction inside skin cells. Mitochondria produce energy (ATP) and manage reactive oxygen species (ROS). With age, cardiolipin in the inner mitochondrial membrane oxidizes. This disrupts electron transport chain efficiency, lowers ATP output, raises ROS leakage, and impairs cell repair. Fibroblasts then make less collagen and elastin. The result shows up as wrinkles, sagging, slower wound healing, and reduced elasticity. SS-31 research targets this mitochondrial layer rather than surface symptoms.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\n1. If mitochondrial cardiolipin oxidation is part of your skin aging, SS-31 binds cardiolipin directly.  \\n2. Binding stabilizes the inner membrane and preserves supercomplex organization.  \\n3. This improves electron transport efficiency and reduces excess ROS from existing mitochondria.  \\n4. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus — SS-31 (Elamipretide) → mitochondrial. No siblings in scope.\\n\\n## What the evidence actually shows\\n\\nPreclinical work in aged mice shows SS-31 restores redox balance, reduces protein oxidation, and improves mitochondrial quality in heart and skeletal muscle. Human data exist for Barth syndrome (FDA approval noted in late 2025) and trials in heart failure, kidney disease, and primary mitochondrial myopathy. No published human trials test SS-31 on skin endpoints such as wrinkles, elasticity, or collagen. One 2025 mouse study explored exosome-loaded SS-31 against UV skin damage. Tier: preclinical for mitochondrial effects in general; speculative for skin.\\n\\n## What scientists say\\n\\nResearchers describe SS-31 as","tokens_in":26702,"tokens_out":2538,"cost":0,"prev":"genesis","hash":"5a5f76574cc3a718339de8772bba3bc80353ba891e2051743bcbef8952dbf47e"},{"ts":"2026-07-17T02:42:08.138Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-skin","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5a5f76574cc3a718339de8772bba3bc80353ba891e2051743bcbef8952dbf47e","hash":"5300ffdf89b0387cca17d13259fe81c2881e2f35fe775149692419184d45e683"}]}